Seville – 27th May 2021

The Center for Industrial Technological Development (CDTI) once again supports a INFARMADE R&D project. In this case, the titled “FIRST LATEST GENERATION SPECIALTIES FOR THE TREATMENT OF HIGH PREVALENCE PSYCHIATRIC DISORDERS”.

The objective general of this project is the development of the first specialties generic pharmaceutical companies of new last generation medicines for the treatment and improvement of the evolution of high-risk psychiatric illnesses prevalence. Likewise, the resulting medicines will have more expensive prices. cheaper than those used as a reference, which will allow both reducing costs to public health systems, such as expanding the number of patients who can access new state-of-the-art drugs.